Zimmer Partners LP Grows Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

Zimmer Partners LP increased its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 24.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 96,900 shares of the biotechnology company's stock after purchasing an additional 18,900 shares during the period. Zimmer Partners LP owned approximately 0.16% of Ascendis Pharma A/S worth $13,340,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Ascendis Pharma A/S during the 4th quarter worth about $28,000. Jones Financial Companies Lllp lifted its holdings in Ascendis Pharma A/S by 394.0% during the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock valued at $34,000 after buying an additional 197 shares in the last quarter. Blue Trust Inc. lifted its holdings in Ascendis Pharma A/S by 415.2% during the 4th quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock valued at $56,000 after buying an additional 328 shares in the last quarter. Quarry LP bought a new stake in Ascendis Pharma A/S during the 4th quarter valued at about $96,000. Finally, Tower Research Capital LLC TRC lifted its holdings in Ascendis Pharma A/S by 195.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,004 shares of the biotechnology company's stock valued at $138,000 after buying an additional 664 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Morgan Stanley upgraded shares of Ascendis Pharma A/S from an "equal weight" rating to an "overweight" rating and lifted their price objective for the company from $180.00 to $250.00 in a report on Monday, May 5th. Cantor Fitzgerald reiterated an "overweight" rating and set a $200.00 price objective on shares of Ascendis Pharma A/S in a report on Monday, May 12th. Royal Bank of Canada lifted their price objective on shares of Ascendis Pharma A/S from $205.00 to $210.00 and gave the company an "outperform" rating in a report on Friday, May 2nd. Wedbush boosted their price target on shares of Ascendis Pharma A/S from $181.00 to $212.00 and gave the company an "outperform" rating in a report on Friday, May 2nd. Finally, Evercore ISI boosted their price target on shares of Ascendis Pharma A/S from $260.00 to $280.00 and gave the company an "outperform" rating in a report on Friday, May 2nd. One equities research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat, Ascendis Pharma A/S currently has an average rating of "Moderate Buy" and an average target price of $216.07.

Ascendis Pharma A/S Stock Up 1.2%

Shares of NASDAQ ASND traded up $1.95 during trading hours on Friday, hitting $162.00. 212,034 shares of the stock were exchanged, compared to its average volume of 487,685. The company has a market cap of $9.88 billion, a PE ratio of -22.82 and a beta of 0.41. The firm has a fifty day moving average price of $157.41 and a 200-day moving average price of $143.68. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $183.00.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($1.66) EPS for the quarter, missing the consensus estimate of ($1.56) by ($0.10). The company had revenue of $123.97 million for the quarter, compared to analysts' expectations of $98.56 million. As a group, equities analysts anticipate that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.